comparemela.com

Latest Breaking News On - Cardeation capital - Page 1 : comparemela.com

Expansion of Cardeation Capital will bring pioneering health care products for heart disease and stroke patients

Cardiovascular disease (CVD) is the leading cause of death globally responsible for 17 million deaths every year and its toll is expected to rise to over 23 million deaths annually by 2030. CVD also represents a major economic burden with the annual economic cost of CVD estimated to range over $500 billion in the United States alone.

Cardeation Capital expands health care innovation in heart disease and stroke care

Cardeation Capital expands health care innovation in heart disease and stroke care
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Moving Analytics Raises $6M to Increase Virtual Cardiac Rehab Solutions and Expand Team Amidst Telehealth Industry Growth

Moving Analytics Raises $6M to Increase Virtual Cardiac Rehab Solutions and Expand Team Amidst Telehealth Industry Growth Share Article With this round, the company will be able to grow their partner and customer base, increasing enrollment rates and clinical outcomes across the country. Moving Analytics Virtual Cardiac Rehab Through our extensive due diligence and vetting through our partners, we have found Movn to be the most comprehensive and mature solution in the market with stellar proof points and evidence of success. LOS ANGELES (PRWEB) April 19, 2021 Moving Analytics, a telehealth company providing virtual cardiac rehab solutions, today announced it raised $6M in a Series Seed-2 round. The round was led by Aphelion Capital, LLC, through Cardeation Capital, with co-investments by OCA Ventures and Seae Ventures. This investment brings Moving Analytics’ total funding received to date to $9.5M.

MIVI Neuroscience Secures Series B Funding

MIVI Neuroscience Secures Series B Funding News provided by Share this article Share this article EDEN PRAIRIE, Minn., Jan. 21, 2021 /PRNewswire/ MIVI Neuroscience, a medical device company focused on improving clinical outcomes for ischemic stroke patients, today announced the closing of its Series B funding including $35 million in new money plus the conversion of previously issued convertible notes.  The funding was led by a major multinational med-tech company and included participation from new investors Perceptive Advisors, Deerfield Management and Aphelion / Cardeation Capital as well as existing investors including Concord Health Partners.  Raymond James & Associates, Inc. acted as sole placement agent for the transaction.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.